U.S. PHARMACOPEIA

Search USP29  
Small Intestinal Submucosa Wound Matrix
» Small Intestinal Submucosa Wound Matrix is a biologically derived, collagen-based wound care product, translucent and off-white in color. It is obtained from the small intestinal submucosa layer of the domestic pig (Sus scrofa L.). This layer has been mechanically separated from the adjoining layers of the intestine to remove the serosal, mucosal, and muscular elements. The isolated submucosa is chemically cleaned, decellularized, freeze-dried, and terminally sterilized. Small Intestinal Submucosa Wound Matrix also undergoes a viral inactivation; the inactivation method is validated using parvovirus, reovirus, pseudorabies virus, and leukemia retrovirus as the test viruses. By dried weight, Small Intestinal Submucosa Wound Matrix consists of about 70 percent protein, about 20 percent carbohydrate, and about 7 percent lipid. The protein component is primarily collagen type I (approximately 90 percent), with minor amounts of elastin and collagen type III, collagen type IV, and collagen type VI. In addition to these components, additional extracellular matrix components, such as glycosaminoglycans and basic fibroblast growth factor, are also retained.
Packaging and storage— Package in single-use, peel-open pouches that are gas permeable for sterilization purposes. Store under clean, dry conditions at 25, excursions permitted between 15 and 30.
Labeling— The package is labeled to indicate the dimensions of the enclosed Small Intestinal Submucosa Wound Matrix, the expiry date, required storage conditions, and the lot number. The label indicates that the Wound Matrix is sterile if the package is intact, and that the Wound Matrix is designed for single patient, one-time use.
USP Authentic visual references— USP Cultured Rat Pheochromocytoma Reference Photomicrographs. These photomicrographs represent examples of normal and differentiated rat pheochromocytoma cells and are used to assist in ascertaining bioactivity.
Bacterial endotoxins 85 Immerse 70 cm2 of Small Intestinal Submucosa Wound Matrix in 40 mL of LAL Reagent Water. Extract for 60 minutes at 37 with shaking. Remove a 100-µL aliquot to measure the amount of bacterial endotoxins. It contains not more than 20.0 USP Endotoxin Units per 70 cm2.
Sterility 71: meets the requirements.
Fibroblast growth factor-2 content—
Sterile PBS solution— Prepare a sterile solution that contains 8065.0 mg and 200.0 mg of sodium chloride and potassium chloride, respectively, per L of 0.01 M sodium phosphate buffer, pH 7.4.
Test solution— Obtain a 1-cm2 sample of Small Intestinal Submucosa Wound Matrix, weigh, and submerge in 400 µL of Sterile PBS solution. Pulverize the tissue for 90 seconds using a tissue grinder, intermittently checking to be sure the tissue remains immersed in the Sterile PBS solution and becomes homogenized. Centrifuge at 12,000 × g for 5 minutes at 4. Use immediately upon preparation. [NOTE—The Test solution may be stored for short periods at 4 or on ice.]
Procedure— Examine duplicate aliquots of the Test solution by a suitably sensitive ELISA method:1 the analysis is considered valid if the ELISA kit generates a linear standard curve with the square of the correlation coefficient (r2) not less than 0.95, and if the duplicate aliquots of the Test solution yield results that are within 20% of each other. The average content of fibroblast growth factor-2 is not less than 10,000 pg per g of Small Intestinal Submucosa Wound Matrix.
Glycosaminoglycan content—
1,9-Dimethylmethylene blue solution— Mix 95 mL of 0.1 M hydrochloric acid in 500 mL of water. Add 16 mg of 1,9-dimethylmethylene blue, 3.04 g of aminoacetic acid, and 2.37 g of sodium chloride. Dilute with water to 1 L, and adjust to a pH of 3.0 using sterile solutions of either 1.0 M sodium hydroxide or 1.0 M hydrochloric acid. Store in low-actinic glassware.
Sterile PBS solution— Prepare as directed under Fibroblast growth factor-2 content.
Proteinase K solution— Prepare a solution of Tritirachium album proteinase K in water having an activity of 600 units per mL.
Stock heparin standard solution— Prepare a solution containing 1 mg of heparin per mL of water.
Heparin standard curve solutions— Using the Stock heparin standard solution, prepare three solutions containing 20 µg per mL, 50 µg per mL, and 100 µg per mL of heparin, respectively.
Blank solution— Use water.
Test solution— Prepare test samples in duplicate. Accurately weigh about 25 mg of Small Intestinal Submucosa Wound Matrix and cut into small pieces (roughly 2 mm × 2 mm). Transfer to a 1.5-mL microcentrifuge tube, and add 180 µL of Sterile PBS solution and 20 µL of Proteinase K solution. Mix, and incubate the sample at 56 for 15 minutes; during the incubation mix intermittently on a vortex mixer. Cool the sample to room temperature. Dilute with water to obtain a concentration of 12.5 mg of digested Small Intestinal Submucosa Wound Matrix per mL.
Collagen control solution— Accurately weigh about 25 mg of a bovine collagen, type I, that contains less than 1 µg of glycosaminoglycan per mg. Transfer to a 1.5-mL microcentrifuge tube, and add 180 µL of Sterile PBS solution and 20 µL of Proteinase K solution. Mix, and incubate the sample at 56 for 15 minutes; during the incubation mix intermittently on a vortex mixer. Cool the sample to room temperature. Dilute with water to obtain a concentration of 12.5 mg of digested bovine collagen per mL.
Procedure (see Spectrophotometry and Light-Scattering 851)— To triplicate 100-µL aliquots each of Heparin standard curve solutions, Blank solution, Test solution, and Collagen control solution, add 2.5 mL of 1,9-Dimethylmethylene blue solution. Mix on a vortex mixer for 1 second and immediately read the absorbance at 525 nm. Generate a standard curve of absorbance versus concentration using the averages of each Heparin standard curve solution, correcting for the blank, and calculate the regression line and regression coefficient. The concentration of glycosaminoglycan in the Test solution and the Collagen control solution is determined directly from the regression line. If the absorbance of the Test solution is greater than the highest Heparin standard curve solution, then dilute the Test solution appropriately, and repeat the Procedure beginning with “To triplicate 100-µL aliquots.” The test is considered valid if the regression curve has a square of the correlation coefficient (r2) not less than 0.95; the triplicate aliquots of the Test solution and Collagen control solution yield results that are within 20% of each other, respectively; and the average glycosaminoglycan content of the Test solution is statistically greater than the Collagen control solution using one-tailed, unequal variances, t-test at = 0.05. The average glycosaminoglycan content of the Test solution is not less than 2 µg per mg.
Metabolic activity assessment—
Dulbecco's modified Eagle's tissue culture medium— Prepare a solution that contains the components included in the following Table 1:
Table 1
Component Content
(mg per L)
Calcium nitrate, tetrahydrate 100.0
Ferric nitrate, nonahydrate 0.10
Potassium chloride 400.0
Magnesium sulfate, anhydrous 48.840
Sodium chloride 6,000.0
Sodium bicarbonate 1,500.0
Sodium phosphate, dibasic (anhydrous) 800.0
Glucose 4,500.0
Glutathione (reduced) 1.0
Phenol red 5.0
Sodium pyruvate 110.0
L-Arginine (free base) 200.0
L-Asparagine, monohydrate 56.620
L-Aspartic Acid 20.0
L-Cystine dihydrochloride 65.20
Aminoacetic acid 10.0
L-Histidine (free base) 15.0
Hydroxy-L-proline 20.0
L-Isoleucine 50.0
L-Leucine 50.0
L-Lysine hydrochloride 40.0
L-Methionine 15.0
L-Phenylalanine 15.0
L-Proline 20.0
L-Serine 30.0
L-Threonine 20.0
L-Tryptophan 5.0
L-Tyrosine, disodium, dihydrate 28.830
L-Valine 20.0
D-Biotin 0.20
D-Calcium pantothenate 2.50
Choline chloride 3.0
Folic acid 1.0
Inositol 35.0
Nicotinamide 1.0
p-Aminobenzoic acid 1.0
Pyridoxine hydrochloride 1.0
Riboflavin 0.20
Thiamine hydrochloride 1.0
Cyanocobalamine 0.0050
MTT reagent— Use a suitable solution of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide.2
Detergent reagent— Use a suitable sodium dodecyl sulfate detergent solution.3
Procedure— Remove three 12-mm diameter circular sections of Small Intestinal Submucosa Wound Matrix, using the appropriate size biopsy punch. Immerse each section into individual wells of a 12-well cell culture plate (dimension of each well is about 22 to 23 mm in diameter and about 17 to 18 mm in depth), each containing 1 mL of Dulbecco's modified Eagle's tissue culture medium. Prepare a positive control by harvesting a full-thickness section of porcine jejunum immediately following slaughter. Rinse the section of jejunum in 37 isotonic sodium chloride solution for 5 minutes to remove intestinal debris. Using scissors, split open the section of jejunum to form a sheet. Remove three 12-mm diameter circular sections of jejunum, using the appropriate size biopsy punch. Immerse each section into individual wells of a 12-well cell culture plate, each well containing 1 mL of Dulbecco's modified Eagle's tissue culture medium. Treat these positive control wells in the same manner as the test wells. Prepare a blank solution using 1 mL of Dulbecco's modified Eagle's tissue culture medium. Allow sections to hydrate for 5 minutes, add 50 µL of MTT reagent to each of the sections and the blank, and mix. Incubate for 3 hours at 37 in an atmosphere containing 5% carbon dioxide. Add 100 µL of Detergent reagent to each well, and mix. Leave the samples at ambient temperature in the dark for 2 hours. Measure the absorbance of the resulting solution at 570 nm, adjusting for the blank. For the test to be valid, the average absorbance in the positive control wells is greater than 0.100. The average absorbance reading for the Small Intestinal Submucosa Wound Matrix wells is less than 0.100.
Bioactivity— [NOTE—Aseptic cell culture techniques should be employed throughout the performance of this test.]
Modified RPMI-1640 culture medium— Prepare a sterile solution that contains the components included in the following Table 2:
Table 2
Component Content
(mg per L)
Calcium chloride 264.9
Ferric nitrate, nonahydrate 0.10
Potassium chloride 400.0
Magnesium sulfate, heptahydrate 200.0
Sodium chloride 6,400.0
Sodium bicarbonate 3,700.0
Sodium phosphate, monobasic,
monohydrate
125.0
Glucose 4,500.0
Phenol red 15.0
Sodium pyruvate 110.0
L-Arginine hydrochloride 84.0
L-Cystine 48.0
Aminoacetic acid 30.0
L-Histidine hydrochloride,
monohydrate
42.0
L-Isoleucine 104.8
L-Leucine 104.8
L-Lysine hydrochloride 146.2
L-Methionine 30.0
L-Phenylalanine 66.0
L-Serine 42.0
L-Threonine 95.2
L-Tryptophan 16.0
L-Tyrosine 72.0
L-Valine 93.6
L-Calcium pantothenate 4.0
Choline chloride 4.0
Folic acid 4.0
Inositol 7.0
Nicotinamide 4.0
Pyridoxine hydrochloride 4.0
Riboflavin 0.40
Thiamine hydrochloride 4.0
Sodium 1-heptanesulfonic acid 2383.0
Penicillin–streptomycin solution— Prepare a suitable buffered solution containing 10,000 USP Penicillin Units of penicillin per mL and 10 mg of streptomycin per mL.4
PC12 cell line culture medium— Mix 420 mL of Modified RPMI-1640 culture medium, 50 mL of horse serum,5 25 mL of fetal bovine serum,6 and 5 mL of Penicillin–streptomycin solution. Sterilize by passing through a 0.22-µm filter.
Sterile PBS solution— Prepare as directed under Fibroblast growth factor-2 content.
Rat tail collagen solution— Prepare a suspension containing 0.2 mg of rat tail collagen, type I, in sterile water.
Cell culture apparatus— Prepare by adding a sufficient volume of Rat tail collagen solution to completely cover the bottom of each well of a 12-well cell culture plate (dimension of each well is about 22 to 23 mm in diameter and about 17 to 18 mm in depth). Incubate under sterile conditions for 2 hours at 37 or overnight at room temperature. Remove the Rat tail collagen solution by aspiration. Rinse with Sterile PBS solution that has been preheated to 37.
PC12 cells— Use cultured rat pheochromocytoma cells (ATCC CRL-1721).
Cultivation of PC12 cells— Starting from a frozen culture, prewarm PC12 cell line culture medium to 37. Add 15 mL of prewarmed PC12 cell line culture medium to a T-75 culture flask. Place a single vial containing the frozen PC12 cells in a 37 water bath with gentle agitation until they start to thaw (about 1 minute). Complete the thawing procedure by slowly rotating the vial between the hands. Rinse the outside of the vial with 70 percent alcohol. Transfer the contents of the vial to the T-75 flask, and mix. Incubate the cells overnight at 37 in a 5% carbon dioxide atmosphere. Transfer the contents of the T-75 culture flask to a sterile centrifuge tube, centrifuge at 200 × g for 5 minutes at 37, and discard the supernatant. Resuspend the cells in 15 mL of PC12 cell line culture medium, and transfer the contents back into the T-75 culture flask. Incubate the cells at 37 in a 5% carbon dioxide atmosphere for 3 days.
Cell feeding— At the end of 3 days, the cells will need to be fed for optimal growth. To feed the cells, remove a flask of cells from the incubator, tightening the cap in the process. Examine the T-75 flask under the microscope and check for microbial contamination and confluency. If there is microbial contamination, then discard the flask. If the cells appear confluent, follow the instructions below for perpetuating the PC12 cell line (see Culture perpetuation). Otherwise, harvest the cells from the flask by pipeting the contents of the flask across the bottom of the flask several times. Transfer the cell suspension to a sterile 50-mL centrifuge tube. Centrifuge the cells at 200 × g for 5 minutes at 37, and discard the supernatant. Resuspend the cells in 13 mL of PC12 cell line culture medium, prewarmed to 37. Transfer the cell suspension back to the T-75 flask, and mix. Loosen the cap of the flask, and return to the incubator; incubate the cells at 37 in a 5% carbon dioxide atmosphere for another 3 to 7 days.
Culture perpetuation— To perpetuate a line of PC12 cells for culture, examine under the microscope a T-75 flask containing cells and check for microbial contamination and confluency. If there is microbial contamination, discard the flask and use another. If the cells do not appear confluent, then follow the instructions above for feeding the PC12 cell line (see Cell feeding), beginning with “Otherwise, harvest the cells from the flask by pipeting the contents of the flask across the bottom of the flask several times.” If the cells are confluent and there is no contamination, harvest the cells from the flask by pipeting the contents of the flask across the bottom of the flask several times to loosen up the cells from their attachment to the bottom of the flask and to break up cell clusters. Check under the microscope prior to proceeding to ensure that most of the cells have detached from the plastic. Transfer the cell suspension to a sterile 50-mL centrifuge tube, and centrifuge the cells at 200 × g for 5 minutes at 37. Discard the supernatant and resuspend the cells with 10 mL of PC12 cell line culture medium, prewarmed to 37. Dispense an equal amount of the cell suspension into each of three to five T-75 flasks, each flask containing 10 mL of PC12 cell line culture medium, prewarmed to 37, and mix. Return the passed cells to the incubator, being sure to loosen the cap of the flasks. Incubate the cells at 37 in a 5% carbon dioxide atmosphere. Feed the cells after 3 days as directed above, beginning with “To feed the cells, remove a flask of cells from the incubator, tightening the cap in the process.” [NOTE—To perform the test for Bioactivity, cells that have undergone more than 15 passages after obtaining them from ATCC should not be used.]
Positive control solution— Prepare a solution containing about 10 ng of fibroblast growth factor-2 per mL of PC12 cell line culture medium.
Negative control solution— Use PC12 cell line culture medium.
Test solution— Immerse 70 cm2 of Small Intestinal Submucosa Wound Matrix in sterile water for 5 minutes. Remove the Small Intestinal Submucosa Wound Matrix, and blot excess water using sterile gauze. Weigh the rehydrated Small Intestinal Submucosa Wound Matrix to the nearest 0.1 g and add Modified RPMI-1640 culture medium at a ratio of 7.5 mL of Modified RPMI-1640 culture medium for each 1.0 g of Small Intestinal Submucosa Wound Matrix. Incubate for 24 hours at 37 with constant shaking. Remove the Small Intestinal Submucosa Wound Matrix, and pass the solution through a 0.22-µm filter. Add sufficient quantities of sterile horse serum and sterile fetal bovine serum to concentrations of 10% and 5%, respectively, and add a sufficient quantity of Penicillin–streptomycin solution such that there are 100 USP Penicillin Units and 0.1 mg of streptomycin per mL. Adjust the pH of the Test solution to 7.4, using a sterile solution of either 1.0 M sodium hydroxide or 1.0 M hydrochloric acid.
Procedure— Harvest a flask of confluent PC12 cells by centrifuging at 200 × g for 5 minutes. Remove the supernatant by aspiration, and resuspend the pellet to obtain a concentration of about 1 × 106 cells per mL of PC12 cell line culture medium. Add to each of three wells of the Cell culture apparatus 1.0 mL of Negative control solution. To a second set of three wells add to each 1.0 mL of Positive control solution, and to a third set of three wells add to each 1.0 mL of Test solution. Add to each well about 20,000 cells, mix by gentle rocking, and incubate for 48 hours at 37. For each well, count three random microscopic fields of cells using a microscope with a 10× ocular lens and a 20× objective lens. Each field should have at least 20 cells; avoid large clumps of cells where individual cell bodies cannot be ascertained. Determine the total number of cells in the field and, using USP Cultured Rat Pheochromocytoma Reference Photomicrographs of normal and differentiated rat pheochromocytoma cells for comparison, determine the total number of cells that have formed at least one neurite-like extension at least twice the diameter of a normal, undifferentiated cell body. For each experimental group, record the total number of cells counted and the total number of cells differentiated across all three wells, and calculate the total percentage of cells that have differentiated. For a test to be valid, the following criteria must be met: (1) none of the wells are microbially contaminated; (2) the weighted percentage of differentiated cells across the Negative control solution wells is less than 5%; (3) the weighted percentage of differentiated cells across the Positive control solution wells is greater than 6%; and (4) the weighted percentage of differentiated cells across the Negative control solution wells is statistically less than the weighted percentage of differentiated cells across the Positive control solution wells, using a one-sided, two-sample test for proportions at = 0.05. The weighted percentage of differentiated cells incubated in the Test solution wells is statistically greater than those incubated in the Negative control solution wells, using a one-sided, two-sample test for proportions at = 0.05.
Residual solvents 467: meets the requirements.
(Official January 1, 2007)

1  A suitably sensitive ELISA test kit for the quantitation can be obtained from R&D Systems Inc., 614 McKinley Place N.E., Minneapolis, MN (www.bioscience.org/company/r&d.htm); product number DFB50.
2  A suitable solution of 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide can be obtained from American Type Culture Collection, P.O. Box 1549, Manassas, VA (www.atcc.org).
3  A suitable sodium dodecyl sulfate detergent reagent can be obtained from American Type Culture Collection, P.O. Box 1549, Manassas, VA (www.atcc.org).
4  A suitable buffered solution containing 10,000 USP Penicillin Units of penicillin per mL and 10 mg streptomycin per mL can be obtained from Sigma-Aldrich Corp., St. Louis, MO (www.sigma-aldrich.com).
5  A suitable horse serum can be obtained from American Type Culture Collection, P.O. Box 1549, Manassas, VA (www.atcc.org).
6  A suitable fetal bovine serum can be obtained from American Type Culture Collection, P.O. Box 1549, Manassas, VA (www.atcc.org).
Auxiliary Information— Staff Liaison : Anita Y. Szajek, Senior Scientist
Expert Committee : (BBCGT05) Biologics and Biotechnology - Cell and Gene Therapy
USP29–NF24 Page 2268
Pharmacopeial Forum : Volume No. 30(5) Page 1652
Phone Number : 1-301-816-8325